Loading...
XPARBOI
Market cap482mUSD
Dec 24, Last price  
26.70EUR
1D
3.09%
1Q
-16.43%
Jan 2017
-68.28%
Name

Boiron SA

Chart & Performance

D1W1MN
XPAR:BOI chart
P/E
12.94
P/S
0.94
EPS
2.06
Div Yield, %
42.92%
Shrs. gr., 5y
-0.49%
Rev. gr., 5y
-3.98%
Revenues
493m
-7.67%
290,633,000361,646,000398,674,000434,471,000466,894,000526,279,000520,600,000523,452,000566,294,000617,988,000609,984,000607,962,000614,491,000617,542,000604,216,000557,123,000513,582,000455,201,000534,239,000493,248,000
Net income
36m
-19.80%
20,592,00016,415,00010,245,00027,157,00039,184,00059,889,00043,283,00042,264,00049,626,00082,396,00089,049,00073,932,00077,725,00078,243,00057,459,00040,630,00026,209,00028,556,00044,673,00035,827,000
CFO
45m
-24.31%
34,403,00041,738,00038,569,00056,130,00065,479,00080,202,00051,638,00058,821,00088,594,000107,017,00096,156,000103,164,000110,131,000104,745,00084,250,00051,555,00068,676,00033,879,00060,099,00045,491,000
Dividend
Jun 03, 20241.35 EUR/sh

Profile

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary, proprietary, branded homeopathic medicines. Its branded homeopathic medicines include Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; and Sédatif PC to treat anxiety and emotional, and minor sleep disorders. The company's homeopathic medicines also comprise Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; and Homéovox for vocal disorders. In addition, it provides dietary supplement; Dermoplasmine stick, baume, and mousse to treat dry lips and skin; Mag' Nuit, a formula to fall asleep; Arnitrosium for joint pain; Castor Equi Boiron ointment for treatment of cracked skin; and Storinyl, a syrup to treat colds. Further, it offers herbal medicines, such as Canephron to increase the amount of urine and to improve urinary elimination; moisturizing baby milk; and medical devices, including a range of COVID self-tests and rapid antigenic tests. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
IPO date
Mar 25, 1991
Employees
2,813
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
493,248
-7.67%
534,239
17.36%
455,201
-11.37%
Cost of revenue
373,757
470,314
407,106
Unusual Expense (Income)
NOPBT
119,491
63,925
48,095
NOPBT Margin
24.23%
11.97%
10.57%
Operating Taxes
12,911
13,685
16,288
Tax Rate
10.80%
21.41%
33.87%
NOPAT
106,580
50,240
31,807
Net income
35,827
-19.80%
44,673
56.44%
28,556
8.95%
Dividends
(198,969)
(16,502)
(16,643)
Dividend yield
Proceeds from repurchase of equity
(122)
(11,539)
(4,744)
BB yield
Debt
Debt current
7,057
5,428
4,887
Long-term debt
16,662
16,738
7,719
Deferred revenue
Other long-term liabilities
65,727
67,396
78,344
Net debt
(65,853)
(234,916)
(226,271)
Cash flow
Cash from operating activities
45,491
60,099
33,879
CAPEX
(9,858)
(18,591)
(20,418)
Cash from investing activities
(22,926)
(15,277)
(11,921)
Cash from financing activities
(198,413)
(28,986)
(22,557)
FCF
96,005
46,555
11,790
Balance
Cash
74,044
250,945
234,504
Long term investments
15,528
6,137
4,373
Excess cash
64,910
230,370
216,117
Stockholders' equity
319,015
484,443
453,185
Invested Capital
406,019
409,251
399,904
ROIC
26.15%
12.42%
8.00%
ROCE
25.37%
9.99%
7.81%
EV
Common stock shares outstanding
17,362
17,389
17,516
Price
Market cap
EV
EBITDA
145,116
95,753
81,466
EV/EBITDA
Interest
1,191
1,537
537
Interest/NOPBT
1.00%
2.40%
1.12%